Featured Research

from universities, journals, and other organizations

Pill may represent promising treatment for stubborn blood cancers, study finds

Date:
March 10, 2014
Source:
American Society of Hematology
Summary:
A pill that suppresses a key regulator of cancer growth may provide hope to relapsed leukemia and lymphoma patients running out of treatment options for their aggressive, treatment-resistant disease, according to three reports. Patients with blood cancer are typically administered a combination of chemotherapy and immunotherapy, the latter using the body's own immune system to help fight disease, as a first line of treatment. While chemotherapy has traditionally been successful in destroying cancer cells, it is accompanied by many harmful side effects and patients typically develop resistance, prompting researchers to investigate new targeted therapies that may be able to block the production of cancer cells while leaving normal cells unharmed.

A pill that suppresses a key regulator of cancer growth may provide hope to relapsed leukemia and lymphoma patients running out of treatment options for their aggressive, treatment-resistant disease, according to three reports published online in Blood, the journal of the American Society of Hematology.

Related Articles


Patients with blood cancer are typically administered a combination of chemotherapy and immunotherapy, the latter using the body's own immune system to help fight disease, as a first line of treatment. While chemotherapy has traditionally been successful in destroying cancer cells, it is accompanied by many harmful side effects and patients typically develop resistance, prompting researchers to investigate new targeted therapies that may be able to block the production of cancer cells while leaving normal cells unharmed.

One such targeted therapy, called idelalisib, is a highly selective compound that, unlike chemotherapy, can target a specific mechanism that fuels cancer growth. Taken as a pill, idelalisib first targets and then blocks the expression of the delta isoform of the PI3 kinase enzyme, which is critical for the activation and survival of cancerous B cells. Idelalisib's narrow targeting of the PI3 kinase delta make it an attractive potential therapy for patients with cancers that form in the B-cell pathway such as chronic lymphocytic leukemia (CLL), indolent non-Hodgkin lymphoma (iNHL), and mantle cell lymphoma (MCL). While idelalisib is currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of treatment-resistant iNHL, another drug in its class called ibrutinib, which specifically targets a different cell regulator, has been approved as a second-line therapy for CLL and MCL.

"Idelalisib is a part of a revolutionary new class of treatments that can hone in on a specific target without causing the wide range of side effects seen with chemotherapy," said study author Jennifer R. Brown, MD, PhD, Director of the Chronic Lymphocytic Leukemia Center at Dana-Farber Cancer Institute in Boston.

In three manuscripts published in Blood, investigators present data from a large Phase I study evaluating the safety and efficacy of idelalisib in more than 150 patients with CLL, iNHL, and MCL. Before joining the trial, patients had received several previous treatments -- some as many as 14 -- that either failed to destroy the disease or provided only a temporary reprieve. After an initial study involving all trial participants, patients were separated into CLL, iNHL, and MCL disease cohorts and received varied doses of idelalisib. The therapy appeared to be effective, as patients suffered few side effects and demonstrated promising response rates, with 72 percent of CLL patients, 47 percent of iNHL patients, and 40 percent of MCL patients achieving either a complete or partial response.

"Considering the high number of previous therapies that these patients had received, higher than we sometimes see in comparable studies, the efficacy of idelalisib that we observed was remarkable," said study author Ian Flinn, MD, PhD, Director of the Hematologic Malignancies Research Program at Sarah Cannon Research Institute in Nashville and a widely recognized expert in lymphoma. "It was this initial excitement that has inspired further studies of this therapy in patients with treatment-resistant blood cancers."

While patients in the CLL and iNHL cohorts experienced significant and prolonged reduction of disease activity, patients with MCL, a more aggressive and treatment-resistant type of lymphoma, experienced less favorable responses. Despite MCL patients' high overall response rate of 40 percent to idelalisib, the duration of their response to the drug was not as impressive; only a small fraction (22%) enjoyed prolonged benefits. Despite the modest duration of survival facilitated by idelalisib in the MCL group, the strong response rate suggests that investigators have identified a key regulator of cancer growth; however, more research is needed to further understand the potential of this therapy in MCL patients.

"While idelalisib is unlikely to receive designation as a single-agent therapy in mantle cell lymphoma due to the short duration of response, the path forward will likely include administering it in combination with other agents or developing second-generation PI3 kinase inhibitors," said study author Brad S. Kahl, MD, Director of the Lymphoma Service at the University of Wisconsin Carbone Cancer Center in Madison. "This study offers a strong foundation for future research on idelalisib in this disease."=


Story Source:

The above story is based on materials provided by American Society of Hematology. Note: Materials may be edited for content and length.


Journal References:

  1. J. R. Brown, J. C. Byrd, S. E. Coutre, D. M. Benson, I. W. Flinn, N. D. Wagner-Johnston, S. E. Spurgeon, B. S. Kahl, C. Bello, H. K. Webb, D. M. Johnson, S. Peterman, D. Li, T. M. Jahn, B. J. Lannutti, R. G. Ulrich, A. S. Yu, L. L. Miller, R. R. Furman. Idelalisib, an inhibitor of phosphatidylinositol 3 kinase p110, for relapsed/refractory chronic lymphocytic leukemia. Blood, 2014; DOI: 10.1182/blood-2013-11-535047
  2. I. W. Flinn, B. S. Kahl, J. P. Leonard, R. R. Furman, J. R. Brown, J. C. Byrd, N. D. Wagner-Johnston, S. E. Coutre, D. M. Benson, S. Peterman, Y. Cho, H. K. Webb, D. M. Johnson, A. S. Yu, R. G. Ulrich, W. R. Godfrey, L. L. Miller, S. E. Spurgeon. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood, 2014; DOI: 10.1182/blood-2013-11-538546
  3. B. S. Kahl, S. E. Spurgeon, R. R. Furman, I. W. Flinn, S. E. Coutre, J. R. Brown, D. M. Benson, J. C. Byrd, S. Peterman, Y. Cho, A. Yu, W. R. Godfrey, N. D. Wagner-Johnston. Results of a phase I study of idelalisib, a PI3K inhibitor, in patients with relapsed or refractory mantle cell lymphoma (MCL). Blood, 2014; DOI: 10.1182/blood-2013-11-537555

Cite This Page:

American Society of Hematology. "Pill may represent promising treatment for stubborn blood cancers, study finds." ScienceDaily. ScienceDaily, 10 March 2014. <www.sciencedaily.com/releases/2014/03/140310111800.htm>.
American Society of Hematology. (2014, March 10). Pill may represent promising treatment for stubborn blood cancers, study finds. ScienceDaily. Retrieved November 22, 2014 from www.sciencedaily.com/releases/2014/03/140310111800.htm
American Society of Hematology. "Pill may represent promising treatment for stubborn blood cancers, study finds." ScienceDaily. www.sciencedaily.com/releases/2014/03/140310111800.htm (accessed November 22, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, November 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

WFP: Ebola Risks Heightened Among Women Throughout Africa

WFP: Ebola Risks Heightened Among Women Throughout Africa

AFP (Nov. 21, 2014) Having children has always been a frightening prospect in Sierra Leone, the world's most dangerous place to give birth, but Ebola has presented an alarming new threat for expectant mothers. Duration: 00:37 Video provided by AFP
Powered by NewsLook.com
Could Your Genes Be The Reason You're Single?

Could Your Genes Be The Reason You're Single?

Newsy (Nov. 21, 2014) Researchers in Beijing discovered a gene called 5-HTA1, and carriers are reportedly 20 percent more likely to be single. Video provided by Newsy
Powered by NewsLook.com
Milestone Birthdays Can Bring Existential Crisis, Study Says

Milestone Birthdays Can Bring Existential Crisis, Study Says

Newsy (Nov. 21, 2014) Researchers find that as people approach new decades in their lives they make bigger life decisions. Video provided by Newsy
Powered by NewsLook.com
Ebola: Life Without School in Guinea

Ebola: Life Without School in Guinea

AFP (Nov. 21, 2014) Following the closure of schools and universities in Guinea because of the Ebola virus, students look for temporary work or gather in makeshift classrooms to catch up on their syllabus. Duration: 02:14 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins